PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31544544-6 2019 Antagonists against cysteinyl leukotriene receptor (CysLTR) type 1, including montelukast, pranlukast and zafirlukast, have been widely prescribed in clinical practices; however, some clinical trials have shown insignificant responses to LTRAs in adult asthmatics, while some phenotypes of adult asthma showed more favorable responses to LTRAs including aspirin-exacerbated respiratory disease, elderly asthma, asthma associated with smoking, obesity and allergic rhinitis. Aspirin 354-361 cysteinyl leukotriene receptor 1 Homo sapiens 52-58 17924829-0 2007 CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. Aspirin 85-92 cysteinyl leukotriene receptor 1 Homo sapiens 0-7 17641958-0 2007 Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. Aspirin 63-70 cysteinyl leukotriene receptor 1 Homo sapiens 33-40 17641958-3 2007 As in vivo functional study, changes of peripheral mRNA level of CysLTR1 were measured by real-time PCR before and after aspirin challenge. Aspirin 121-128 cysteinyl leukotriene receptor 1 Homo sapiens 65-72 17641958-6 2007 The CysLTR1 mRNA levels increased significantly after aspirin challenge in AIA patients (P = 0.013). Aspirin 54-61 cysteinyl leukotriene receptor 1 Homo sapiens 4-11 17641958-7 2007 In conclusion, the CysLTR1 polymorphism may contribute to develop to the AIA phenotype and be used as a genetic marker for differentiating two major aspirin hypersensitivity phenotypes. Aspirin 149-156 cysteinyl leukotriene receptor 1 Homo sapiens 19-26 16630147-0 2006 Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Aspirin 74-81 cysteinyl leukotriene receptor 1 Homo sapiens 0-32 16630147-2 2006 CysLTR1-selective antagonists have anti-bronchoconstrictive and anti-inflammatory effects in asthma, particularly aspirin-intolerant asthma (AIA). Aspirin 114-121 cysteinyl leukotriene receptor 1 Homo sapiens 0-7 16505607-2 2006 RECENT FINDINGS: The overproduction of cysteinyl leukotrienes with the increased expression of cysteinyl leukotriene receptor 1 (CYSLTR1) is a consistent finding in aspirin-induced asthma patients. Aspirin 165-172 cysteinyl leukotriene receptor 1 Homo sapiens 95-127 16505607-2 2006 RECENT FINDINGS: The overproduction of cysteinyl leukotrienes with the increased expression of cysteinyl leukotriene receptor 1 (CYSLTR1) is a consistent finding in aspirin-induced asthma patients. Aspirin 165-172 cysteinyl leukotriene receptor 1 Homo sapiens 129-136 12421891-6 2002 RESULTS: The absolute number of cells expressing the CysLT1 receptor was significantly higher in the aspirin-sensitive patients than in the non-aspirin-sensitive patients (median, 542 cells per square millimeter [range, 148 to 1390] vs. 116 cells per square millimeter [range, 40 to 259]; P<0.001). Aspirin 101-108 cysteinyl leukotriene receptor 1 Homo sapiens 53-59 12421891-6 2002 RESULTS: The absolute number of cells expressing the CysLT1 receptor was significantly higher in the aspirin-sensitive patients than in the non-aspirin-sensitive patients (median, 542 cells per square millimeter [range, 148 to 1390] vs. 116 cells per square millimeter [range, 40 to 259]; P<0.001). Aspirin 144-151 cysteinyl leukotriene receptor 1 Homo sapiens 53-59 12421891-7 2002 The percentage of CD45+ leukocytes expressing the CysLT1 receptor was also higher in the aspirin-sensitive subjects (25 percent of CD45+ leukocytes [range, 4 to 50] vs. 5 percent of CD45+ leukocytes [range, 2 to 11]; P<0.001); the percentage of CD45+ leukocytes expressing the LTB4 receptor did not differ significantly between these two groups. Aspirin 89-96 cysteinyl leukotriene receptor 1 Homo sapiens 50-56 12421891-9 2002 CONCLUSIONS: The elevated numbers of nasal inflammatory leukocytes expressing the CysLT1 receptor in aspirin-sensitive patients with chronic rhinosinusitis as compared with their non-aspirin-sensitive counterparts and the down-regulation of receptor expression after desensitization to aspirin are probably fundamental in the pathogenesis of aspirin sensitivity and in the mechanism of aspirin desensitization. Aspirin 101-108 cysteinyl leukotriene receptor 1 Homo sapiens 82-88 12421891-9 2002 CONCLUSIONS: The elevated numbers of nasal inflammatory leukocytes expressing the CysLT1 receptor in aspirin-sensitive patients with chronic rhinosinusitis as compared with their non-aspirin-sensitive counterparts and the down-regulation of receptor expression after desensitization to aspirin are probably fundamental in the pathogenesis of aspirin sensitivity and in the mechanism of aspirin desensitization. Aspirin 183-190 cysteinyl leukotriene receptor 1 Homo sapiens 82-88 12421891-9 2002 CONCLUSIONS: The elevated numbers of nasal inflammatory leukocytes expressing the CysLT1 receptor in aspirin-sensitive patients with chronic rhinosinusitis as compared with their non-aspirin-sensitive counterparts and the down-regulation of receptor expression after desensitization to aspirin are probably fundamental in the pathogenesis of aspirin sensitivity and in the mechanism of aspirin desensitization. Aspirin 183-190 cysteinyl leukotriene receptor 1 Homo sapiens 82-88 12421891-9 2002 CONCLUSIONS: The elevated numbers of nasal inflammatory leukocytes expressing the CysLT1 receptor in aspirin-sensitive patients with chronic rhinosinusitis as compared with their non-aspirin-sensitive counterparts and the down-regulation of receptor expression after desensitization to aspirin are probably fundamental in the pathogenesis of aspirin sensitivity and in the mechanism of aspirin desensitization. Aspirin 183-190 cysteinyl leukotriene receptor 1 Homo sapiens 82-88 12421891-9 2002 CONCLUSIONS: The elevated numbers of nasal inflammatory leukocytes expressing the CysLT1 receptor in aspirin-sensitive patients with chronic rhinosinusitis as compared with their non-aspirin-sensitive counterparts and the down-regulation of receptor expression after desensitization to aspirin are probably fundamental in the pathogenesis of aspirin sensitivity and in the mechanism of aspirin desensitization. Aspirin 183-190 cysteinyl leukotriene receptor 1 Homo sapiens 82-88 34429873-7 2021 Variations in the expression of cysteinyl leukotriene receptor 1 in the airways could additionally influence the response to long-term aspirin therapy. Aspirin 135-142 cysteinyl leukotriene receptor 1 Homo sapiens 32-64 15696087-0 2005 Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. Aspirin 75-82 cysteinyl leukotriene receptor 1 Homo sapiens 50-58 15696087-0 2005 Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. Aspirin 97-104 cysteinyl leukotriene receptor 1 Homo sapiens 50-58 15696087-3 2005 We previously compared expression of cysLT 1 on mucosal leukocytes in patients with aspirin-sensitive and aspirin-tolerant rhinosinusitis. Aspirin 84-91 cysteinyl leukotriene receptor 1 Homo sapiens 37-44 15696087-3 2005 We previously compared expression of cysLT 1 on mucosal leukocytes in patients with aspirin-sensitive and aspirin-tolerant rhinosinusitis. Aspirin 106-113 cysteinyl leukotriene receptor 1 Homo sapiens 37-44 15696087-4 2005 OBJECTIVE: To compare expression of cysLT 1 and cysLT 2 on leukocytes, mucus glands, and epithelium in 32 patients with chronic polypoid rhinosinusitis (21 aspirin-sensitive, 11 aspirin-tolerant) and 9 normal controls. Aspirin 156-163 cysteinyl leukotriene receptor 1 Homo sapiens 36-43 15696087-6 2005 RESULTS: The percentages of mucosal CD45 + leukocytes expressing cysLT 1 were significantly ( P < .0001) elevated in the aspirin-sensitive but not the aspirin-tolerant patients compared with the controls. Aspirin 124-131 cysteinyl leukotriene receptor 1 Homo sapiens 65-72 15696087-9 2005 CONCLUSION: Although cysLT 1 expression predominates on inflammatory leukocytes in patients with aspirin-sensitive rhinosinusitis, the effects of cysteinyl leukotrienes on glands and epithelium may be mediated predominantly through cysLT 2. Aspirin 97-104 cysteinyl leukotriene receptor 1 Homo sapiens 21-28 11141472-8 2001 These results indicate that ATL and LTD(4) bind and compete with equal affinity at CysLT(1), providing a molecular basis for aspirin-triggered LXs serving as a local damper of both vascular CysLT(1) signals as well as ALX receptor-regulated polymorphonuclear leukocyte traffic. Aspirin 125-132 cysteinyl leukotriene receptor 1 Homo sapiens 83-91 11141472-8 2001 These results indicate that ATL and LTD(4) bind and compete with equal affinity at CysLT(1), providing a molecular basis for aspirin-triggered LXs serving as a local damper of both vascular CysLT(1) signals as well as ALX receptor-regulated polymorphonuclear leukocyte traffic. Aspirin 125-132 cysteinyl leukotriene receptor 1 Homo sapiens 190-198